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EDITORIAL REVIEW
f32-microglobulin: Its significance in the evaluation of renal
function
J32-microglobulin (/32M) was isolated in 1968 by Berggârd and
Beam [1] from the urine of patients with Wilson's disease and
chronic cadmium poisoning, both conditions characterized pri-
marily by proximal tubular damage. This discovery was fol-
lowed by extensive investigations regarding its structure, func-
tion, metabolism and its role in the evaluation of renal function
[2-4].
f32M is a low molecular weight (LMW) protein of 11.800
daltons composed of 100 aminoacids with one disulphide bridge
[5] (Fig. 1).
/32M has been identified as the light chain of the class I major
histocompatibility antigens (HLA—A, B and C) (Fig. 2). They
are found on the cell surface of all nucleated cells by which they
are synthesized [6]. 132M is non-covalently attached to the
heavy chain and is essential to its serological specificity. The
HLA molecule loses its serological specificity when not at-
tached to /32M.
As a result of metabolism and degradation of HLA, /32M is
dissociated from the heavy chain and appears in its free form in
the extracellular fluid. This process is called "shedding." There
is also the possibility that J32M is excreted in its free form from
the cells or is released after their destruction. At least 95% of
f32M in plasma or urine is present as the free monomer, only a
very small quantity being associated with other molecules [4].
Methodology of measurement
/32M can be measured in plasma, serum, urine and other
human fluids like saliva, cerebrospinal or pleural fluids. It is
usually measured by radioimmunoassay or enzyme—linked im-
munosorbent assay (Elisa). These methods are most reliable.
Other methods like gel electrophoresis, radial immunodiffusion
and nephelometric assays have been described. Normal serum
values are 1.1 to 2.7 mg/liter and the normal urinary excretion is
<370 p.g/24 hr. There is no disagreement between investigators
concerning the measurement of thM in serum or plasma [7—151.
The interpretation of the results of urinary p2M determinations
is sometimes a matter of discussion.
The instability of urinary f32M has been a matter of disagree-
ment between different investigators. All agree that f32M is
unstable at room temperature, in urine with a pH < 5.5.
However, at body temperature a rapid and irreversible loss of
132M occurs in urine with a pH <6.0 and in urine of patients
receiving gentamicin [8, 16]. Furthermore, loss of /32M near
neutral pH, caused by enzymes released from leukocytes and
neutrophil granulocytes, may sometimes be found in pyuria
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[17]. This whole pattern of instability is probably caused by
proteolytic enzymes, as these processes are inhibited by pre-
heating the urine to 80°C or addition of low doses of specific
enzyme inhibitors [16, 17].
As urine is normally stored in the human bladder for at least
two hours before voiding, we advise ensuring production of
urine with a pH 6.0. This can be achieved by giving alkali to
the patients before and during urine collection rather than
adding alkali to the urine after voiding [8].
To ensure a urinary pH 6.0, the subject should be given 4
g of sodium bicarbonate on the evening preceding the experi-
ment, and another 4 g in four divided doses the following day,
during the 24 hour collection. With these measures most urine
collections have a pH of 6 or more. Only urine specimens with
a pH ' 6.0 should be assayed.
Production and turnover of /32-microglobulin
Turnover studies with I'25-labelled f32M in humans have
shown that the production in normal adults is 0.11 to 0.18
mg/hr/kg (mean 0.13 mg/hr/kg) or 150 to 200 mg f32M daily [7].
Elimination of the protein occurs almost completely by the
kidney through glomerular filtration. In normal persons, with a
normal glomerular filtration rate (GFR) there is a rapid turnover
of f32M (t '/z = 2.1 hr) and serum concentration amounts to a
mean of 2.0 mg/liter (range 1.0 to 2.7 mg/liter) [8].
Increased serum values in the presence of a normal GFR
indicate increased f32M production. This has been observed in
lymphoproliferative diseases, autoimmune diseases like SLE,
immune system associated diseases (Crohn's disease, chronic
hepatitis, sarcoidosis, vasculitis), in patients with AIDS and in
some malignant diseases like Hodgkin's disease, non-Hodgkin
lymphoma, leukemia and in multiple myeloma [3, 4].
Renal handling of /32-microglobulin
About 95% of all free /32M is filtered by the normal glomerulus
and subsequently almost completely reabsorbed and catabo-
lized by the cells of the proximal tubules. j32M enters the cells
by endocytosis. The endocytic vesicles fuse with lysosomes,
where the reabsorbed proteins are degraded to amino acids.
A normal kidney is able to reabsorb about 99.9% of the
filtered j32M, which means that maximally 370 g/24 hr is
excreted in the urine [3]. Malfunction of the proximal tubules
with a normal GFR will be accompanied by a decreased tubular
reabsorption and an increased urinary excretion of /32M.
Intravenous infusions of ornithine, arginine and especially
lysine [9, 10] cause transient tubular proteinuria, probably
through temporary blocking of tubular membrane receptors.
The greatly—increased protein excretion, in particular 132M,
returns to normal levels within one hour. Lysine is especially
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effective causing the excretion of /32M to rise to exceptionally
high values of about 60% of the amount filtered.
The circadian rhythm of urinary f32M excretion has been
studied in normal humans and in patients with the nephrotic
syndrome [II]. Twelve of 20 patients had a "normal" circadian
rhythm for $2M excretion with a maximum around 15 hours and
a minimum around 4 hours. The others had different excretion
patterns. The day—night variability in the excretion of /32M is
also present in the absence of clinically important proteinuria.
As /32M easily passes the glomerulus, the increase in urinary
excretion during daytime is probably of tubular origin [11].
j32-mlcroglobulin and glomerular filtration rate
As /32M leaves the body almost exclusively through glomer-
ular filtration, there is an inverse correlation between serum
/32M and GFR (Fig. 3); when GFR decreases both serum /32M
and serum creatinine will increase proportionally. As only
about 1% of the total removal of f32M takes place through
extrarenal pathways [10, 121 serum levels of 132M would be ideal
to evaluate GFR. However in several disease states, there is an
increased production of /32M, resulting in an increased serum
concentration notwithstanding a normal GFR.
/32.microglobulin in early childhood
j32M has been used as an indicator of renal tubular maturation
in infants born from the 32nd to the 41st gestational week [13].
Serum concentration and the amount filtered increase fivefold.
The urinary excretion decreased between the 32 and 35 weeks
and increased again thereafter. These results and those of
others [14] suggest that proximal tubular maturation lags behind
glomerular function and that glomerulo-tubular balance for f32M
occurs at about 35 weeks. Fractional reabsorption of f3M
increases from 87% at 32 weeks of gestational age to 98% at 40.5
weeks, to increase further to 99.9% at 21 months of age, this
being the adult value [15].
Tubular reabsorption capacity for !32-mlcroglobulin
Maximal tubular reabsorption of J32M (Tm$2M) is a matter of
controversy and awaits definite clarification. Human p2M,
although now available, has not yet been used in human
experiments. Observations have been recorded in patients with
increased endogenous production of /32M.
Fivepatients with the hepatorenal syndrome with serum /32M
increased to 8.6 to 15.8 mg/liter, had no increase in urinary f32M
excretion [18]. These and other similar observations cast doubt
on the postulated renal threshold of 4.5 mg/liter for 132M
suggested by Wibell and Evrin [19].
Constant infusions of human /32M to dogs at rates ranging
from 51 to 269 g/min showed that renal extraction exceeded
the rate of glomerular filtration at all levels of /32M delivered to
the kidney [20]. They concluded that 2M is extracted from
renal blood by glomerular filtration and, in addition, by a
mechanism independant of GFR. No apparent saturation point
for uptake of filtered j32M or for that extracted in excess of
filtration which could be demonstrated at arterial delivery rates
as high as 740 p.g/min.
Increased tubular /32-microglobulin reabsorption
In sickle cell nephropathy, a condition characterized by an
increased proximal tubular function, the fractional /32M excre-
tion was found to be decreased. Tubular reabsorption of /32M
was increased and /32M clearances decreased [21].
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Fig. 1. Primary structure and physicochemical characteristics of /32-
microglobulin. From Phadedoc Diagnostic Communications 6; 4: 1979
(Pharmacia Diagnostics AB, Uppsala, Sweden).
Fig. 2. A schematic representation of the HLA complex (class I) with
the heavy chain (right side) penetrating the cytoplasinic membrane and
the light chain being /32-microglobulin attached non-covalently to the
heavy chain. From Phadedoc Diagnostic Communications 6; 9: 1979
(Pharmacia Diagnostics AB, Uppsala, Sweden).
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Fig. 3. The serum levels of 132-microglobulin versus inulin clearance in
61 subjects with normal and decreased GFR. From [12].
Increased urinary fi2-microglobulin excretion in renal disorders
Many pathologic conditions in which the proximal renal
tubule is involved, are accompanied by an increased renal
excretion of /32M as a result of diminished tubular reabsorption.
Two to 36 percent of patients treated with aminoglycosides
develop signs of drug—induced renal functional derangement
[22]. The damage is predominantly restricted to the proximal
tubule, where the aminoglycosides accumulate, reaching con-
centrations that can be more than 50 times as high as the serum
concentration. The result is damage to the brush border of the
proximal tubules, or even their desintegration due to swelling
and rupture of lysozomes, thus leading to autolysis and necrosis
of the cells. An increased renal excretion of brush border and
lysosomal enzymes is observed and a decreased reabsorption of
/32M, preceding the decrease in GFR and elevation of serum
creatinine [22—271.
Experimental studies have revealed some of the basic
pathologic mechanism in aminoglycoside nephrotoxicity [28].
Increased /32M excretion heralds aminoglycoside induced dam-
age before the rise in serum creatinine [22, 24]. Not all patients
on aminoglycoside therapy with increased urinary f32M will
develop severe renal damage. In one study, 71% of these
patients had some elevation of /32M, but only 33% had a rise in
serum creatinine [23]. Comparable observations were made by
others, who observed an increase in f32M four to five days prior
to elevation in serum creatinine. Very high urinary /32M was
observed in patients with cirrhosis of the liver when treated
with aminoglycosides [25].
Although most of the observations were done in patients
treated with gentamicin, aminoglycoside nephrotoxicity has
also been observed during treatment with tobramycin and
amikacin [26]. Aminoglycosides in combination with cytoxins,
especially methotrexate, appear to be excessively nephrotoxic
[27, 28].
In conclusion, it can be stated that about 5 to 10% of patients
treated with aminoglycosides develop serious nephrotoxic re-
actions, characterized primarily by damage to the proximal
tubules. An extremely high excretion of 132M (up to SOto 100mg
daily) can be observed which precedes the decrease in GFR by
about five days. This means that frequent urinary /3M estima-
tions can be useful in early detection of renal damage and allow
discontinuation of these drugs.
In Balkan nephropathy, a chronic tubulointerstitial nephrop-
athy of unknown etiology, with a high prevalence in some areas
of Bulgaria, Romania and Yugoslavia, tubular proteinuria,
especially increased urinary f32M, is one of the first signs of the
disease [29, 30]. It is therefore a suitable screening test in
epidemiological studies [311.
Heavy metals
Most heavy metals accumulate in the kidney and especially in
the proximal tubules. Cadmium (Cd), used in many industries,
has been extensively studied in relation to its renal toxicity. Its
excretion from the kidneys after exposure is very slow (10 to 34
years), which means that its effects on the kidney will be
apparent for many years. The earliest sign is tubular protein-
uria. Cadmium workers may have a 100- to 1,000-fold higher
excretion than normals. Protein excretion was found to be 10 to
20 times higher in smokers than in non-smoking workers due to
contamination of their hands [32]. Population studies in
cadmium—exposed areas in Sweden, Japan and the United
Kingdom showed an increased excretion of /32M in the urine of
the inhabitants, which was related to the duration of the
exposure [33, 34]. In Japan the combination of renal dysfunc-
tion and osteomalacia in these patients is known as Itai—Itai
disease. Cadmium damage of the proximal tubules is usually
irreversible, although in some patients improvement has been
observed after removal from exposure [35].
The renal abnormalities resulting from chronic mercury (Hg)
poisoning, are comparable with those of chronic cadmium
intoxication. A significant increase in renal j32M excretion has
been observed [36]. It is endemic in inhabitants around a small
bay in Minamata in southern Japan. The afflicted persons had
eaten large amounts of fish and shellfish that were extremely
contaminated with methyl mercury discharged from industrial
plants (Minamata disease).
Although lead and gold are known to cause kidney damage,
132M excretion has only been incidently studied in intoxications
with these heavy metals [3]. On the other hand, many observa-
tions have ben made on the nephrotoxicity of cisplatinum
(cis-dichlorodiamine platinum II), a potent anti-tumor agent [37,
38]. In the majority of cases a transient rise in urinary /32M has
been observed [3, 39].
Fanconi's syndrome and other causes of tubular proteinuria
Specific tubular diseases like Fanconi's syndrome, Wilson's
disease, nephrocalcinosis, untreated congenital galactosemia,
chronic potassium depletion, cystinosis and other tubular dis-
eases are characterized by an increased urinary excretion of
/32M. This is also the case with interstitial nephritis of known
and unknown origin [40]. Fractional excretion (FE) of /32M was
significantly lower in children with glomerular lesions than with
tubular lesions (mean 0.104% vs. 4.27%; normal < 0.36%). Of
30 children with glomerulopathies who underwent renal biop-
sies, 13 also had tubulointerstitial lesions. With the exception of
two, all had increased FE-/32M. Those without evidence of
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tubulo-interstitial disease had normal values [41]. This means
that the estimation of FE-132M can be helpful to diagnose
tubulo-interstitial involvement in glomerulopathies.
132-microglobulin and radiocontrast agents
One of the major potential hazards of angiography are ad-
verse effects on the kidneys. Radiocontrast agents may cause a
decrease in renal blood flow, increase in vascular resistance or
have a direct toxic effect on the kidney. All these factors may
lead to a reduction in GFR, a nonselective proteinuria or
sometimes acute renal failure. Risk factors are preexisting renal
disease, advanced age, the volume of contrast material, the
place of administration and diabetes [42, 43].
In a prospective study on 28 patients, aged 28 to 70 years who
underwent coronary angiography, we were able to demonstrate
a significant temporary decrease in GFR and a temporary
increase of urinary alanine aminopeptidase (AAP, a brush
border enzyme), 132M and N-acetyl-f3-glucosaminidase (NAG, a
lysozomal enzyme from the proximal tubules) [40].
fi2-microglobulin in connective tissue diseases
Rheumatoid arthritis
In patients with rheumatoid arthritis renal disease is not
uncommon. Recently, proximal tubular dysfunction was dem-
onstrated in 24% of the patients studied [44]. Another important
factor is the use of numerous potential nephrotoxic agents.
Acute tubular necrosis, interstitial nephritis and analgesic
nephropathy are well known complications [45]. There are
several studies demonstrating the usefulness of 2M for evalu-
ating the toxic influence of gold and cyclosporine on the kidney
tubules [46, 47].
Sjogren syndrome (SS)
For more than 20 years it has been known that renal tubular
dysfunction occurs in SS. Clinical and laboratory findings vary
from a decrease in concentrating capacity, to renal tubular
acidosis or Fanconi syndrome. Tubulointerstitial nephritis and
tubular atrophy have been observed in the majority of kidney
biopsies. Our own observations employing urinary /32M suggest
that proximal tubular dysfunction occurs even in patients with
primary SS, who have not received any pharmacotherapy [45].
Urinary tract infections
In hospital practice it is not always easy to diagnose or
exclude pyelonephritis or to distinguish between upper and
lower UTI. Methods like bladder washout and ureteral cathe-
terization may be the most reliable, but they demand instru-
mentation of the urinary tract with all the hazards of an invasive
technique and the danger of introduction of bacteria. The
technique of fluorescence of antibody coated bacteria looked
promising, but after five years experience this technique ap-
pears to be unreliable [48, 491.
From our own studies [49] thM appears the method of choice
to distinguish between upper and lower UT! (Fig. 4). All
patients with pyelonephritis had a significant increase in 24-
hour urinary f32M excretion. On the other hand, in patients with
cystitis the /32M values were completely normal. There was no
overlap in 24-hour urinary f32M values between the two groups
of patients.
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Moreover, serial measurements of /32M (Fig. 5) are useful to
monitor the efficacy of therapy and the detection of recurrences
in upper UTI [50]. The introduction of urinary 132M estimations
in the management of these patients could well be of great
advantage in the evaluation of treatment and in the prevention
of end stage, pyelonephritic renal disease.
M and renal transplantation
Serum /32M has been extensively investigated in renal trans-
plantation [51—54]. In successful renal transplantation serum
and urinary levels of /32M decreased significantly. Frequent
determinations of serum and urinary f32M after transplantation
represent a sensitive assessment of glomerular and tubular
function in the transplanted kidney. There is much disagree-
ment about the value of serum 132M in the diagnosis of rejection.
Fields et al concluded that an increase in serum /32M has
proven to be a highly sensitive indicator of rejection (97%) and
attains a specificity (84%) comparable with creatinine [53].
These investigators claim that /32M has a distinct advantage
over creatinine: it changes significantly sooner than creatinine.
On the other hand Bflckman et al [54] came to the conclusion
that serum f32M does not differentiate rejection from cyclospo-
rifle toxicity, but may be helpful in the early diagnosis of
cytomegalovirus infection. Some investigators consider signif-
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Fig. 4. Twenty—four-hour urinary excretion of 132-microglobulin in 18
patients with upper, 30 patients with lower urinary tract infections and
44 controls. From [3].
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19 27 ing long—term hemodialysis treatment, the cause being amyloid
deposition. A relationship has been suggested between the high
serum concentration of /32M in hemodialysis patients and the
potential development of amyloidosis, carpal tunnel syndrome
and of amyloid osteo-arthropathy [59], the latter being found
after an average of 13 years (range 7 to 16 years) of hemodial-
ysis.
The prevalence of amyloid osteo-arthropathy increased with
time, but cases were restricted to those patients on hemodial-
ysis with cuprophane membranes. Serum 132M levels were
higher in cuprophane than in polyacrylonitrile dialyzed pa-
tients. Hauglustaine et a! [60] reported values of 50.7 3.9
mg/liter and 44.5 2.7 mg/liter (mean sEM), respectively for
the two groups.
Krediet (personal communication) observed in 19, continu-
ous ambulatory peritoneal dialysis (CAPD) patients, a serum
f32M of 35.0 mg/liter (SEM 2.5 mg/liter), which is in accordance
with a higher permeability of the peritoneal membrane for low
molecular weight (LMW) molecules like f32M.
These values are significantly lower than those of hemodial-
ysis patients mentioned above. f32M amyloidosis has not yet
been observed in CAPD patients.
By its unique property of being almost exclusively filtered by
the glomerulus and most efficiently (99.9% of the amount
filtered) reabsorbed by the cells of the proximal tubules under
diverse physiologic conditions, renal /32M excretion has proven
to be a very sensitive method in diagnosing proximal tubular
disorders. Many of these have been extensively investigated
and are discussed in the present review. Others require more
detailed research, such as the increased urinary /32M excretion
in eclampsia [3], in renal ischemia, shock and acute tubular
necrosis. Renal embolization in one observation resulted in
very high renal 132M excretion [3].
Renal /32M excretion has been successfully employed in
epidemiological surveys in regions with endemic Balkan
nephropathy and in discovering chronic intoxication in areas
polluted by cadmium or other heavy metals.
And finally, urinary /32M has been shown to be the most
reliable test for discriminating between upper and lower urinary
tract infections. It is most useful in evaluating the results of
therapy and in detecting recurrences in acute pyelonephritis by
means of serial determinations.
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Fig. 5. /32-microglobulin in serum and urine in a 69-year—old female
with pyelonephritis and urosepsis, demonstrating the significantly
increased f32-microglobulin excretion and its return to normal with
appropriate therapy. From [3].
icant changes of serum f32M as a useful marker of compromised
renal graft function with discrimanatory capacity and predictive
value for diagnosis of graft rejection [55] or as an adjunct to, but
not a replacement for, classical methods for detecting acute
rejection [52].
In the interpretation of serum and urinary /32M in kidney
transplantation, a decrease of fl2M will reflect improvement of
glomerular and tubular function (tubular uptake and metabo-
lism). An increase of serum and urinary 132M may be caused by
intercurrent multiple pathologic processes like the following:
• renal tubular ischemia: renal artery stenosis, cardiovascu-
lair insufficiency
• infection: pyelonephritis, cytomegalovirus
• post-renal obstruction
• nephrotoxic agents: cyclosporine, aminoglycoside
fi2-microglobulin and hemodialysis
Fibrils with the properties of amyloid have been isolated from
patients with bone and joint involvement complicating chronic
dialysis. Further analysis revealed /32M as a major constituent
of the fibrils [56, 57]. This signifies that /32M is another example
of a low molecular weight, serum protein with a potential
/3-pleated sheet structure, that may adopt the fibrillar configura-
tion of amyloid in certain pathologic states. Two hundred and
one patients on long—term hemodialysis had a significantly
higher serum f32M concentration than normal subjects (41.6
9.6 vs. 1.2 0.6 mg per liter; P < 0.001) [58], and it increased
slightly with the duration of hemodialysis. In patients on
long—term hemodialysis a new form of amyloidosis of bone is
being recognized with the formation of tumoral masses some-
times presenting as pathologic fractures. The carpal tunnel
syndrome has been observed increasingly in patients undergo-
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